

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

9

Application Number

09/446,601

Filing Date

April 3, 2000

First Named Inventor

ABRAMOVICI et al.

Art Unit

1614

Examiner Name

JAGOE, Donna A

Attorney Docket Number

IVD 994 US PCT

**RECEIVED
CENTRAL FAX CENTER****FEB 15 2006****ENCLOSURES (Check all that apply)**

Fee Transmittal Form



Fee Attached



Amendment/Reply



After Final



Affidavits/declaration(s)



Extension of Time Request



Express Abandonment Request



Information Disclosure Statement



Certified Copy of Priority Document(s)

Reply to Missing Parts/
Incomplete ApplicationReply to Missing Parts
under 37 CFR 1.52 or 1.53

Drawing(s)



Licensing-related Papers



Petition

Petition to Convert to a
Provisional Application

Power of Attorney, Revocation



Change of Correspondence Address



Terminal Disclaimer



Request for Refund



CD. Number of CD(s) _____

☐ Landscape Table on CD

Remarks



After Allowance Communication to TC

Appeal Communication to Board
of Appeals and InterferencesAppeal Communication to TC
(Appeal Notice, Brief, Reply Brief)

Proprietary Information




Status Letter

Other Enclosure(s) (please identify
below):**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm Name

sanofi-aventis US Inc.

Signature



Printed name

Kelly L. BENDER

Date

February 15, 2006


Reg. No.

52610

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO. 571-273-8200) Total No. of Pages Transmitted: (9)

Signature



Typed or printed name

Judith Oswald

Date

February 15, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Attorney Docket No. IVD 994 US PCT

Reply under 37 C.F.R. 1.116
Expedited Procedure
Technology Center 1600**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE****RECEIVED
CENTRAL FAX CENTER
FEB 15 2006**In re Application of
Abramovici

Examiner: Donna A. Jagoe

Art Unit: 1614

Application No.: 09/446,601

TELEFAX CERTIFICATE

Filed: April 3, 2000

Title: **Solid Pharmaceutical Compositions
Containing Benzofuran Derivatives**I hereby certify that this correspondence is being
transmitted via facsimile to Mail Stop AF,
Commissioner for Patents, Alexandria, VA 22313, onFebruary 15, 2006
Date of Transmission

Signature

Judith Oswald

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

AMENDMENT AND RESPONSE TO FINAL OFFICE ACTION

This is in response to the Final Office Action mailed on November 16, 2005, by the United States Patent and Trademark Office setting a three-month period for response set to expire on February 16, 2006. This response is therefore timely filed.

Please amend the above-identified application as follows:

In the Claims:

Please amend claims 1, 6, 12 and 13 and cancel claims 5, 9, 10, and 17 as shown below.